Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: Results of a randomized, double-blind study

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue 4, 1999, Pages 529-539

  Shah, P M ^a   Maesen, F P V ^b   Dolmann, A ^c   Vetter, N ^d   Fiss, E ^e   Wesch, R ^f  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Zuyderland Medical Centre   (Netherlands)

^c Hospital Zonal de Agudos y Cronicos Dr Antonio A Cetrangolo   (Argentina)

^d Pulmonologisches Zentrum Stadt Wien   (Austria)

^e Hospital Oswaldo Cruz   (Brazil)

^f SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CEFUROXIME AXETIL; LEVOFLOXACIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; EOSINOPHILIA; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MORAXELLA CATARRHALIS; MORTALITY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SENSE ORGAN; SIDE EFFECT; SKIN DISEASE; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

EID: 0032909077     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/43.4.529     Document Type: Article

References (26)

1. Vogel, F. (1995). A guide to the treatment of lower respiratory tract infections. Drugs 50, 62-72.
2. Langtry, H. D. & Lamb, H. M. (1998). Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs 56, 487-515.
3. Finch, R. G. (1995). The role of new quinolones in the treatment of respiratory tract infections. Drugs 49, Suppl. e, 144-51.
4. Jensen, T., Pedersen, S. S., Hoiby, N. & Koch, C. (1987). Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis. European Journal of Clinical Microbiology 6, 618-22.
5. Fu, K. P., Lafredo, S. C., Foleno, B., Isaacson, D. M., Barrett, J. F., Tobia, A. J. et al. (1992). In vitro and in viro antibacterial activities of levofloxacin (L-ofloxacin), an optically active ofloxacin. Antimicrobial Agents and Chemotherapy 36, 860-6.
6. Yamane, N., Jones, R. N., Frei, R., Hoban, D. J., Pignatari, A. C. & Marco, F. (1994). Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin. Journal of Chemotherapy 6, 83-91.
7. Chien, S. C., Rogge, M. C., Gisclon, L. G., Curtin, C., Wong, F., Natarajan, J. et al. (1997). Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrobial Agents and Chemotherapy 41, 2256-60.
8. Fish, D. N. & Chow, A. T. (1997). The clinical pharmacokinetics of levofloxacin. Clinical Pharmacokinetics 32, 101-19.
9. Honeybourne, D., Andrews, J. M., Jevons, G., Brenward, N. P., Cunningham, B. & Wise, R. (1997). Penetration of levofloxacin (HR355) into lung tissues after a single 500 mg oral dose. In Program and Abstracts of the Eighth European Congress of Clinical Microbiology and Infectious Diseases, Lausanne, Switzerland, 1997, Abstract P377, p. 84. European Society of Clinical Microbiology and Infectious Diseases, Taufkirchen, Germany,
10. Nagai, H., Yamasaki, T., Masuda, M., Goto, Y., Tasiro, T. & Nasu, M. (1993). Penetration of levofloxacin into bronchoalveolar lavage fluid. Drugs 46, Suppl. 3, 259,
11. DeAbate, C. A., Russell, M., McElvaine, P., Faris, H., Upchurch, J., Fowler, C. L. et al. (1997). Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respiratory Care 42, 206-13.
12. File, T. M., Segreti, J., Dunbar, L., Player, R., Kohler, R., Williams, R. R. et al. (1997). A multicentre, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrobial Agents and Chemotherapy 41, 1865-72.
13. Habib, M. P., Gentry, L. O., Rodriguez-Gomez, G., Morowitz, W. & Williams, R. (1996). A multicenter randomized study comparing the efficacy and safety of oral levofloxacin vs cefaclor in the treatment of acute bacterial exacerbations of chronic bronchitis. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1996, Abstract LM2, p. 280. American Society of Microbiology, Washington, DC.
14. Landau, Z., Pitlik, S. & Schlaffer, F. (1992). Cefuroxime axetil vs augmentin for the treatment of acute bronchitis and exacerbation of chronic obstructive pulmonary disease. Israel Journal of Medical Sciences 28, 797-9.
15. Nolen, T. M., Phillips, H. L., Hutchinson, J. & Cocchetto, D. M. (1988). Comparison of cefuroxime axetil and cefaclor for patients with lower respiratory tract infections presenting to a rural family practice clinic. Current Therapeutic Research 44, 821-9.
16. Schleupner, C. J., Anthony, W. C., Tan, J., File, T. M., Lifland, P., Craig, W. et al. (1988). Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections. Archives of Internal Medicine 148, 343-8.
17. Shah, S. H., Shah, I. S., Turnbull, G. & Cunningham, K. (1994). Cefuroxime axetil in the treatment of bronchitis: comparison with amoxycillin in a multicentre study in general practice patients. British Journal of Clinical Practice 48, 185-9.
18. Beam, T. R., Gilbert, D. N. & Kunin, C. M. (1992). General guidelines for the clinical evaluation of anti-infective drug products. Clinical Infectious Diseases 15, Suppl. 1, S5-32.
19. National Committee for Clinical Laboratory Standards. (1994). Performance Standards for Antimicrobial Disk Susceptibility Tests -Fifth Edition: Approved Standard M2-A5. NCCLS, Villanova, PA.
20. Fleiss, J. L. (1981). Statistical Methods for Rates and Proportions. Wiley, New York.
21. Harkins, R. D. & Albrecht, R. (1990). Design and analysis of clinical trials for anti-infective drug products. Drug Information Journal 24, 213-24.
22. Makuch, K. & Simon, R. (1978). Sample size requirements for evaluating a conservative therapy. Cancer Treatment Reports 62, 1037-40.
23. Anthonisen, N. R., Manfreda, J., Warren, C. P. W., Hershfield, E. S., Harding, G. K. M. & Nelson, N. A. (1987). Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine 106, 196-204.
24. Ball, P. (1994). Efficacy and safety of cefprozil vs other β-lactam antibiotics in the treatment of lower respiratory tract infections. European Journal of Clinical Microbiology and Infectious Diseases 13, 851-6.
25. Grossman, R. F. (1992). Cefaclor AF vs cefaclor in acute exacerbations of chronic bronchitis. Postgraduate Medical Journal 68, Suppl. 3, S30-7.
26. Zeckel, M. L. (1992). Loracarbef (LY 163892) in the treatment of acute exacerbations of chronic bronchitis: results of US and European comparative clinical trials. American Journal of Medicine 92, Suppl. 6A, 58S-64S.